Bretaris Genuair 322 μg

Bretaris Genuair is a product of Astra Zeneca Ab

Group: Approved Anticholinergic Agents

Name: Bretaris Genuair

Dosage:

Strength: 322 μg

Route: Respiratory (inhalation)

Pharmaceutical company : Astra Zeneca Ab

You can also find other alternative products such as : Eklira Genuair (322 μg) from Astra Zeneca Ab Bretaris Genuair (322 μg) from Astra Zeneca Ab Eklira Genuair (322 μg) from Astra Zeneca Ab Eklira Genuair (322 μg) from Astra Zeneca Ab Eklira Genuair (322 μg) from Astra Zeneca Ab Eklira Genuair (322 μg) from Astra Zeneca Ab Bretaris Genuair (322 μg) from Astra Zeneca Ab Bretaris Genuair (322 μg) from Astra Zeneca Ab Bretaris Genuair (322 μg) from Astra Zeneca Ab

Indication: Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Category:

  • Adrenergics, Inhalants
  • Agents to Treat Airway Disease
  • Alkaloids
  • Anticholinergic Agents
  • Antimuscarinics Antispasmodics
  • Aza Compounds
  • Azabicyclo Compounds
  • Drugs for Obstructive Airway Diseases
  • Muscarinic Antagonists
  • Food Interactions; Not Available

    Aclidinium Definition:
    Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

    More Bretaris Genuair 322 μg

    ALPHANATE Rx

    Therapeutic indications Bleeding disorders


    Warnings/Precautions: Not for those with severe VWD undergoing major surgery..Indications for ALPHANATE: Prevention and control of bleeding in Hemophilia A or acquired Factor VIII deficiency.. Blood groups A, B or AB; large and/or frequent dosing may result in hemolytic anemia..


    ALPHANATE Rx

    Therapeutic indications Bleeding disorders


    Warnings/Precautions: Not for those with severe VWD undergoing major surgery..C).. Note: Report all infections suspected to be transmitted by Alphanate to (888) GRIFOLS..


    Plasma Human, Blood Group AB Solution

    Therapeutic indications Consult your pharmacist or physician

    fda.. You may report side effects to Health Canada at 1-866-234-2345..gov/medwatch..
    **Interactions**Consult your pharmacist or physician..Keep a list of all your medications with you, and share the list with your doctor and pharmacist..


    Octaplas (Blood Group AB) 45 To 70 Mg/Ml Intravenous Solution

    Therapeutic indications Consult your pharmacist or physician

    Consult your pharmacist or physician.. You may report side effects to Health Canada at 1-866-234-2345..fda..
    **Precautions**Consult your pharmacist or physician..Keep a list of all your medications with you, and share the list with your doctor and pharmacist..**Interactions**Consult your pharmacist or physician..


    Drug mixture that contained Aclidinium

    Name Pharmaceutical
    Duaklir Genuair Astra Zeneca Ab
    Duaklir Genuair Astra Zeneca Ab
    Duaklir Genuair Astra Zeneca Ab
    Duaklir Genuair Astra Zeneca Ab

    Effects of Bretaris Genuair 322 μg by reaction with another drug or drugs

  • Methantheline may increase the anticholinergic activities of Aclidinium.
  • Acetylsalicylic acid may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • Pemetrexed may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • Tolcapone may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • The risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with WIN 55212-2.
  • Spironolactone may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
  • Oxybutynin may increase the anticholinergic activities of Aclidinium.
  • Aclidinium may decrease the excretion rate of Warfarin which could result in a higher serum level.
  • The risk or severity of adverse effects can be increased when Scopolamine is combined with Aclidinium.
  • Phenglutarimide may increase the anticholinergic activities of Aclidinium.
  • Tenofovir disoproxil may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • The serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.
  • The risk or severity of adverse effects can be increased when Clidinium is combined with Aclidinium.
  • The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Aclidinium.
  • Nabumetone may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • Esomeprazole may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • Fondaparinux may decrease the excretion rate of Aclidinium which could result in a higher serum level.
  • Aclidinium may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
  • The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Aclidinium.
  • The risk or severity of adverse effects can be increased when Quetiapine is combined with Aclidinium.